A Phase 2 interventional study of NLY01 and Placebo in Multiple Sclerosis, sponsored by Johns Hopkins University. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Johns Hopkins University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Multiple Sclerosis by Johns Hopkins University — 4 open to participants now, 5 under way, none of them phase 3. Multiple Sclerosis · Johns Hopkins University.
Among the 20 studies in Multiple Sclerosis by Johns Hopkins University, this one is the 3rd largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 in phase 2, and was the 20th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →4 of the 20 studies in Multiple Sclerosis by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–65
Johns Hopkins University · Sites in United States
Ages 18–60
Johns Hopkins University · Sites in United States
Ages 18–70
By country, each count listing its studies:
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 2 · Phase 4 2
First in 2010; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 48 across the 18 interventional studies, 50 across the 2 observational. Of the 14 that completed or were terminated, 7 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Johns Hopkins University is the lead sponsor of 1,817 studies on the registry; 316 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
2 of the studies in Multiple Sclerosis by Johns Hopkins University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06170970Johns Hopkins UniversitySolriamfetol for the Treatment of Multiple Sclerosis Fatigue | 2026-12-01 |
| NCT06167642Johns Hopkins UniversityRetinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Multiple Sclerosis by Johns Hopkins University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate if the study drug will reduce brain and retinal atrophy by reducing inflammation and subsequently slowing neurodegeneration in people with Multiple Sclerosis. The main outcome for the trial is change in normalized brain parenchymal volume (nBPV), measured by magnetic resonance imaging (MRI).
Researchers will compare outcomes from participants randomized to the study drug, versus participants randomized to placebo, to see if there are signs of slowed neurodegeneration (i.e., reduction in brain and retinal atrophy).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Current or planned (next 2 years) pregnancy/breastfeeding; if able to become pregnant, agree to reliable (contraception requirements as discussed below)***
Contraceptive methods with a failure rate of \< 1% per year includes the following:
Those who do not wish to use one of the above methods of contraception must use two methods. Options include:
Two forms of barrier contraception during sexual encounter with a person who has testes. Examples of barrier contraceptive methods include the following:
A cap, diaphragm, or sponge with or without spermicide
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
5 mg subcutaneous weekly for the first 4 weeks, then 10 mg subcutaneous weekly, with pre-planned dose adjustments if adverse events prevent full dosage.
Drug: NLY01
Drug: Placebo
NLY01 is a pegylated exenatide
Placebo (saline solution)
Change in normalized (for head size) brain parenchymal volume (nBPV)
Change in normalized (for head size) nBPV (mL). Measured from randomization to end of treatment (approximately 96 weeks). Presented as mean and standard deviation
Time frame: Baseline, week 48, and week 96
Change in normalized gray matter volume (mL)
Presented as mean and standard deviation Measured from randomization to end of treatment (approximately 96 weeks).
Time frame: Baseline, week 48, and week 96
Change in thalamic volume (mL)
Measured from randomization to end of treatment (up to 96 weeks). Presented as mean and standard deviation.
Time frame: Baseline, week 48, and week 96
Change in cortical thickness (mm)
Measured from randomization to end of treatment (approximately 96 weeks), Presented as mean and standard deviation.
Time frame: Baseline, week 48, and week 96
Change in retinal nerve fiber layer thickness
Measured in μm, from randomization to end of treatment (approximately 96 weeks),
Time frame: Baseline, week 48, and week 96
Change in ganglion cell/inner plexiform thickness
Measured in μm, from randomization to end of treatment (approximately 96 weeks),
Time frame: Baseline, week 48, and week 96
Disability progression as assessed by the Expanded Disability Status Scale (EDSS)
Expanded Disability Status Scale (EDSS). Scale range 0-10; higher score is worse disability progression
Time frame: Approximately every 24 weeks, up to 96 weeks
Disability progression as assessed by the Multiple Sclerosis Functional Composite (MSFC)
The Multiple Sclerosis Functional Composite (MSFC) calculates a single Z-score from tests of ambulation, arm dexterity, and cognition. Scores are converted to a z score with a mean and standard deviation. A higher Z-score indicates better function.
Time frame: Approximately every 24 weeks, up to 96 weeks
Disability progression as assessed by the Expanded Disability Status Scale-Plus
The EDSS-plus allows for documentation of progression as a composite value, considering progression as having occurred if any one of the following occurs: 20% increase in timed 25-foot walk or 9-hole peg test, or a 1.0-point increase in EDSS (if baseline is 5.5 or less) or a 0.5-point increase (if baseline is \>5.5).
Time frame: Approximately every 24 weeks, up to 96 weeks
Patient-reported disability progression as assessed by the Patient-Determined Disease Steps
Patient-Determined Disease Steps score range 0-8; higher is worse progression
Time frame: Approximately every 24 weeks, up to 96 weeks
Change in self-reported anxiety as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Anxiety Subscale
Quality of Life in Neurological Disorders (Neuro-QOL) Anxiety Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.
Time frame: Approximately every 24 weeks, up to 96 weeks
Change in self-reported depression as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Depression Subscale
Quality of Life in Neurological Disorders (Neuro-QOL) Depression Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.
Time frame: Approximately every 24 weeks, up to 96 weeks
Change in self-reported fatigue as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Fatigue Subscale
Quality of Life in Neurological Disorders (Neuro-QOL) Fatigue Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.
Time frame: Approximately every 24 weeks, up to 96 weeks
Change in self-reported upper extremity function as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Upper Extremity Function Subscale
Quality of Life in Neurological Disorders (Neuro-QOL) Upper Extremity Function Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.
Time frame: Approximately every 24 weeks, up to 96 weeks
Change in self-reported lower extremity function as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Lower Extremity Function Subscale
Quality of Life in Neurological Disorders (Neuro-QOL) Lower Extremity Function Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.
Time frame: Approximately every 24 weeks, up to 96 weeks
Change in self-reported cognitive function as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Cognitive Function Subscale
Quality of Life in Neurological Disorders (Neuro-QOL) Cognitive Function Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.
Time frame: Approximately every 24 weeks, up to 96 weeks
Change in positive affect/well-being as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Positive Affect/Well-being Subscale
Quality of Life in Neurological Disorders (Neuro-QOL) Positive Affect/Well-being Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.
Time frame: Approximately every 24 weeks, up to 96 weeks
Change in self-reported sleep disturbance as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Sleep Disturbance Subscale
Quality of Life in Neurological Disorders (Neuro-QOL) Sleep Disturbance Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.
Time frame: Approximately every 24 weeks, up to 96 weeks
Change in self-reported ability to participate in social roles Quality of Life in Neurological Disorders (Neuro-QOL) Ability to Participate in Social Roles Subscale
Quality of Life in Neurological Disorders (Neuro-QOL) Ability to Participate in Social Roles Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.
Time frame: Approximately every 24 weeks, up to 96 weeks
Change in self-reported stigma as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Stigma Subscale
Quality of Life in Neurological Disorders (Neuro-QOL) Stigma Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.
Time frame: Approximately every 24 weeks, up to 96 weeks
Adverse events
Proportion of individuals in each arm experiencing adverse events
Time frame: From randomization to week 96
Serious adverse events
Proportion of individuals in each arm experiencing serious adverse events
Time frame: From randomization to week 96
Plan to share: Yes — De-identified individual participant data (IPD) that underlie the results reported in this publication, along with the protocol and analysis plan, will be available upon reasonable request to qualified researchers. Requests must include a proposal and are contingent on meeting regulatory approvals, including a signed data use agreement.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be available 6 months after publication and remain accessible for 12-24 months.
Access criteria: Qualified researchers who have completed and signed approvals for data sharing.
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Jan 2030, 45 months after the start.
Of 49 non-industry phase 2 interventional studies under Multiple Sclerosis, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 68. This study's planned 45 months is close to that.
Counting every sponsor, half of 92 studies reached it within 36 months; a quarter within 20 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegsebrenatide